The UK’s clinical trial regulations are changing. Starting from 28 April 2026, a number of updates to the way trials must be run come into force.
Nicola Emmett, LightOx’s Head of Quality and Regulatory Affairs, is responsible for making sure that the company is fully prepared from a quality and regulatory perspective, as it moves towards clinical trials for its lead candidate, LXD191 – a light-activated treatment for early stage oral cancers.
Here, Nicola outlines some of the main changes the regulation reform brings, and shares her perspective on how it could change the UK’s reputation as a location for trials.
The key changes in the new UK clinical trial regulations
The new regulations are designed to make clinical trials faster and more proportionate based on risk, while still maintaining high safety and ethical standards.
They combine and streamline regulatory and ethics review, introduce a more risk‑based approach, and allow lower risk and early phase trials to be assessed much more quickly, potentially within 14 days.
The updated framework also places much clearer transparency requirements on trial registration and results reporting, strengthening public trust while still supporting innovation.
Ultimately these changes are intended to help safe and effective treatments reach patients sooner.
You can read more about the changes to the regulations here.
Accelerating treatment development
For companies preparing to enter the clinic, the changes bring clearer pathways and quicker timelines, which makes planning much more predictable. This is particularly important for innovative biotech companies like LightOx, where time and investment are critical.
The ability for lower risk trials to be accepted rapidly can significantly accelerate early development.
At the same time, the new system expects sponsors to be well prepared, with high quality data, clear justification of risk, and a strong approach to transparency built in from the outset.
Making the UK more attractive for clinical trials
Faster approvals, acceptance of lower risk trials within very short timelines, and a more pragmatic, proportionate regulatory approach all make the UK significantly more competitive.
The increased transparency requirements also help build confidence among patients, clinicians and investors.
Preparing for clinical trials – what SMEs can underestimate
When it comes to preparing for clinical trials, one of the most underestimated aspects is how early quality, regulatory and transparency planning needs to start.
In smaller companies, those responsibilities often sit alongside other critical operational areas, so it’s essential to think holistically from the beginning. Decisions made early on around data quality, risk classification, governance and processes can have a major impact later on, particularly if you want to benefit from accelerated approval routes.
Getting those fundamentals right early not only reduces regulatory risk but also helps ensure that effective and safe products can move through development more efficiently and reach patients sooner.
In any early stage company, it’s about putting the right foundations in place so we can develop safely, efficiently and with confidence, with the understanding that our ultimate end customer is always the patient.
Knowing that the work we do here at LightOx can ultimately improve patients’ lives is what genuinely spurs me on in my role.
LightOx is preparing to take its lead candidate, LXD191, to phase 1 clinical trials. Find out more about the pipeline here.
